Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection - Wikidata - awgldk - TriplyDB

Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection

Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection

http://www.wikidata.org/entity/Q33979426

about

Dose optimisation of antibiotics in children: application of pharmacokinetics/pharmacodynamics in paediatrics Pharmacological properties of NAI-603, a well-tolerated semisynthetic derivative of ramoplanin.Exploring the collaboration between antibiotics and the immune response in the treatment of acute, self-limiting infections Use of vancomycin pharmacokinetic-pharmacodynamic properties in the treatment of MRSA infections What do we really know about antibiotic pharmacodynamics?Population pharmacokinetics of teicoplanin in children.Murine immune response to a chronic Staphylococcus aureus biofilm infection In vitro and in vivo pharmacokinetics-pharmacodynamics of GV143253A, a novel trinem.Pharmacodynamics of oritavancin (LY333328) in a neutropenic-mouse thigh model of Staphylococcus aureus infection Pharmacokinetic-pharmacodynamic analysis of spiroindolone analogs and KAE609 in a murine malaria model.Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC In vivo pharmacodynamic activity of the glycopeptide dalbavancin Setting and revising antibacterial susceptibility breakpoints.Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine.Influence of pharmacokinetics/pharmacodynamics of antibacterials in their dosing regimen selection.Pharmacodynamics of vancomycin for CoNS infection: experimental basis for optimal use of vancomycin in neonates.Pharmacodynamics of antibiotics to treat multidrug-resistant Gram-positive hospital infections.Continuous versus intermittent infusion of vancomycin for the treatment of Gram-positive infections: systematic review and meta-analysis.Emerging drugs on methicillin-resistant Staphylococcus aureus.Pharmacodynamics of teicoplanin against MRSA.Simulation of concentration-time profiles of benzyl-penicillin, enrofloxacin and dihydrostreptomycin in tissue cages in calves.The bacteriocin sublancin attenuates intestinal injury in young mice infected with Staphylococcus aureus.Combined therapy of teicoplanin and caffeic acid phenethyl ester (CAPE) in the treatment of experimental mediastinitis in the rat.Experimental study of teicoplanin, alone and in combination, in the therapy of cephalosporin-resistant pneumococcal meningitis.Addition of fusidic acid impregnated bone cement to systemic teicoplanin therapy in the treatment of rat osteomyelitis.Systemic inflammatory response syndrome criteria and vancomycin dose requirement in patients with sepsis.Medullary plasma pharmacokinetics of vancomycin after intravenous and intraosseous perfusion of the proximal phalanx in horses.Differential Activity of the Combination of Vancomycin and Amikacin on Planktonic vs. Biofilm-Growing Staphylococcus aureus Bacteria in a Hollow Fiber Infection Model.Immunogene therapy with fusogenic nanoparticles modulates macrophage response to Staphylococcus aureus.

P2860

Q26853629-E5C42F65-6FB2-4ABD-A80A-7A1164AE4A88 Q33622948-E2F726BD-1EA7-4C8D-8CF6-3C7DC54BFAA7 Q33767602-D15BAF24-D53A-428C-8A1C-5CC3F30B9C3F Q33881584-99271326-A5A3-483A-8B22-D3B0D06F9A97 Q34443407-1F4AF4D1-D52E-4AC5-BB0D-54753091D451 Q34596321-51E79BCC-87B1-49C2-A941-0AEA416C15DB Q34740325-F3B6AD80-F9A8-4BA3-8D1B-A7366066A5A1 Q34824344-4A3672DF-D1E6-4199-A760-69DC704B5A31 Q34937444-B29B5783-A0DA-4144-BCE8-5AA8AC117E62 Q35105913-39986E4B-6CF7-4925-A313-E7218ED7A33D Q35637864-9C7090E8-FC29-4293-A376-281805E9006A Q35759076-565F0597-8948-4F69-894A-3D3071A543F4 Q35913176-AA42FED6-A4A6-4AC6-9582-747C834FD913 Q35985436-1C5A3CED-2A94-45B7-9E30-A01F60E12AB6 Q36505518-672C1ADE-1B3E-44FF-972E-0974D269387E Q36684184-6769A1D7-5DBB-41B5-8133-221899F42730 Q36777850-40684432-D3C5-4D25-9425-A80FF0771D64 Q37949553-3CF39F33-5358-4BBF-9690-6BFBEB77174E Q38121142-FD38454C-AC86-4608-9813-BCD8A8BEAB34 Q41992893-F2E4CB3D-E1B1-4927-BD05-174249BBFB53 Q44210255-267D1E44-87AD-41C5-A9AE-F4888118E88F Q44244001-DB57DDBE-6CF4-4A39-9EC7-3859F1EC86DE Q44406594-203E622F-85D5-44DB-8109-FC38270E6898 Q44591792-7A7DCC7E-2809-4A93-B725-95487CF6698D Q44839678-BB3BFBCF-C975-4270-9343-9F767415D726 Q45163883-3257CCBE-816E-4056-97AA-981996DDE183 Q46846785-01FFBDB0-0306-4C8A-85AF-477E31D8FD7B Q52595189-1D0A6253-F778-415B-AD44-487C4EEDD6D0 Q54207404-5EBF7A9C-074B-4666-9554-A5DE206E5EB1

P2860

Pharmacodynamics of glycopeptides in the mouse peritonitis model of Streptococcus pneumoniae or Staphylococcus aureus infection

http://www.wikidata.org/entity/Q33979426

description

2000 nî lūn-bûn

@nan

2000 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2000 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2000年の論文

@ja

2000年学术文章

@wuu

2000年学术文章

@zh-cn

2000年学术文章

@zh-hans

2000年学术文章

@zh-my

2000年学术文章

@zh-sg

2000年學術文章

@yue

name

Pharmacodynamics of glycopepti ...... taphylococcus aureus infection

@ast

Pharmacodynamics of glycopepti ...... taphylococcus aureus infection

@en

type

label

Pharmacodynamics of glycopepti ...... taphylococcus aureus infection

@ast

Pharmacodynamics of glycopepti ...... taphylococcus aureus infection

@en

prefLabel

Pharmacodynamics of glycopepti ...... taphylococcus aureus infection

@ast

Pharmacodynamics of glycopepti ...... taphylococcus aureus infection

@en

P1433

Q33979426-ED212741-BDD5-445A-A974-2591493284BB

P1476

Q33979426-83E932F9-5430-41BB-BEC2-07CB337135A1

P2093

Q33979426-3A08104F-9C96-43B5-9B63-8974CC320730

Q33979426-94BE905F-E7FE-4234-8480-F510EC6C8819

Q33979426-C5D83C53-3CC5-4AE9-B95A-7C03DE7EAB23

Q33979426-E691E724-2F6F-4435-A0FD-CF7E689198E2

Q33979426-EB77999D-A688-4B0E-AC24-09A227F6B92B

P2860

Q33979426-06F2890C-132B-4168-868E-6F5AE44577D7

Q33979426-0B51E2B0-8B3F-4811-A7F2-A8B69B457A87

Q33979426-0D00689B-D530-4187-AC94-4C00439E923E

Q33979426-5CC54A06-717D-4AAD-AA60-807F611F379A

Q33979426-6BF34042-45B7-4763-AEDE-DF3339A43223

Q33979426-732829F8-A92E-4CC5-80A4-C75AAFB499AF

Q33979426-7A65E4AC-1242-47D2-98C5-690F43EC04C3

Q33979426-7E694D52-BA85-436F-B7C2-FFBC7812B204

Q33979426-9EAC1564-BB3D-4986-A6DD-75F74D4E1173

Q33979426-A014A9EE-DB5F-47D4-9189-2A37395C4AF3

P304

Q33979426-DFB040AE-8976-49D5-8FE6-96484F191286

P31

Q33979426-AE839458-9B5A-41CE-AD92-A8B25A57DBD6

P356

Q33979426-87D14370-BA83-4CFD-8055-41BDAAD26BE5

P407

Q33979426-E5E642BA-FC6F-4D55-A884-67EA663221FE

P433

Q33979426-A862E7DB-FEA1-49BC-A406-A9BE8B5608EC

P478

Q33979426-CAE1F95E-064D-434B-BDB2-7D61F0F783D3

P577

Q33979426-08EC1807-02FF-451C-BF11-6BF292692A00

P5875

Q33979426-D3F947C7-2EAA-472F-B0A6-540EA2F6296D

P698

Q33979426-59DEA64A-6DF3-4C27-8C0F-0C71C59577F3

P932

Q33979426-27D9FBD7-F38D-4E9B-828E-7A15523853E0

P356

AAC.44.5.1247-1254.2000

P1433

Antimicrobial Agents and Chemotherapy

P1476

Pharmacodynamics of glycopepti ...... taphylococcus aureus infection

@en

P2093

F Espersen

http://www.w3.org/2001/XMLSchema#string

J D Knudsen

http://www.w3.org/2001/XMLSchema#string

K Fuursted

http://www.w3.org/2001/XMLSchema#string

N Frimodt-Moller

http://www.w3.org/2001/XMLSchema#string

S Raber

http://www.w3.org/2001/XMLSchema#string

P2860

Serum vancomycin concentrations: reappraisal of their clinical value.

Experimental Streptococcus pneumoniae infection in mice for studying correlation of in vitro and in vivo activities of penicillin against pneumococci with various susceptibilities to penicillin.

Noncompromised penicillin-resistant pneumococcal pneumonia CBA/J mouse model and comparative efficacies of antibiotics in this model.

Activities of vancomycin and teicoplanin against penicillin-resistant pneumococci in vitro and in vivo and correlation to pharmacokinetic parameters in the mouse peritonitis model.

Effects of dosage, peak and trough concentrations in serum, protein binding, and bactericidal rate on efficacy of teicoplanin in a rabbit model of endocarditis.

A critical review of the dosage of teicoplanin in Europe and the USA.

Antistaphylococcal activities of teicoplanin and vancomycin in vitro and in an experimental infection

Pharmacokinetic optimisation of vancomycin therapy.

Teicoplanin: 10 years of clinical experience.

Multiply-resistant pneumococcus: therapeutic problems in the management of serious infections.

P304

1247-1254

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.44.5.1247-1254.2000

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

44

http://www.w3.org/2001/XMLSchema#string

P577

2000-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

12545402

http://www.w3.org/2001/XMLSchema#string

P698

10770759

http://www.w3.org/2001/XMLSchema#string

P932

89852

http://www.w3.org/2001/XMLSchema#string